PCI PENN UK HOLDCO LIMITED

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“After making reasonable enquiries and assessing forecasts (up to 31 December 2026) including severe, but plausible and downside scenarios, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. This assessment takes into account the recent change in ownership, as detailed in Note 20, which has not adversely affected the group's or the company's financing and / or going concern status. The Group and its subsidiaries (which includes PCI Penn UK Holdco Limited) has financing and facilities which includes a $400M revolving line of credit which is not forecast to be utilised and is part of the available liquidity should the company or group need it. The Group has also provided a letter of support to the company and confirmed its intentions to provide financial support as is necessary for a period of at least 12 months from the date of signing these financial statements. Having taken all of the above considerations into account, the directors have determined that the financial statements should be prepared on a going concern basis.”

Group structure

1. PCI PENN UK HOLDCO LIMITED · parent
   1. Biotec Services International Limited 100% · United Kingdom · Pharmaceutical Services
   2. Penn Pharma Group Limited 100% · United Kingdom · Holding Company
   3. AndersonBrecon (UK) Limited 50% · United Kingdom · Pharmaceutical Services
   4. Millmount Healthcare Limited 100% · Ireland · Pharmaceutical Services
   5. Penn Pharmaceuticals Services Limited 100% · United Kingdom · Pharmaceutical Services

Significant events

• “On 11 July 2025, the current owners of the Parent Company (KPCI Holdings Ltd.) entered into a recapitalisation agreement with Maverick Intermediate Holdings Limited (buyer), valuing the Group at approximately $9.8bn. Following regulatory approval, the recapitalisation took place on 15 October 2025. This agreement led to the merger of the buyer's subsidiary into KPCI Holdings Ltd., with KPCI Holdings Ltd. surviving, and Maverick Holdings, LP becoming the new ultimate parent company for the group. No one party has a greater than 50% shareholding in the Group.”
• “On 13 October 2025, the Company issued 66,357,000 ordinary shares of £1.00 nominal value which were paid up in full by appreciation of the Company's capital contribution reserve balances. A reduction in capital was then undertaken whereby the newly issued share capital in the Company was reduced and credited to distributable reserves. At the same time, the Company received from its fully owned subsidiary, Biotec Services International Limited, a dividend in the amount of £59,074,385. Then, on 15 October 2025, as a part of the recapitalization of the ultimate parent company, the Company borrowed $30,000,000 less fees of $466,745, for net borrowings of $29,533,255 (£22,152,895 at a rate of 0.7501). A dividend was then issued for £81,227,280 to the Company's immediate parent Pioneer UK Holdings Limited, which was ultimately distributed to the ultimate parent KPCI Holdings Ltd. as a part of the recapitalization transaction.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

3

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.